EYESW
Income statement / Annual
Last year (2021), Second Sight Medical Products Inc's total revenue was $260.00,
a decrease of 74.00% from the previous year.
In 2021, Second Sight Medical Products Inc's net income was -$8,921.00.
See Second Sight Medical Products Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$260.00 |
$1,000.00 |
$3.38 M |
$6.90 M |
$7.96 M |
$3.99 M |
$8.95 M |
$3.40 M |
$1.56 M |
$1.37 M |
| Cost of Revenue |
$130.00
|
$500.00
|
$2.15 M
|
$4.89 M
|
$5.12 M
|
$10.08 M
|
$5.29 M
|
$3.56 M
|
$5.63 M
|
$4.40 M
|
| Gross Profit |
$130.00
|
$500.00
|
$1.23 M
|
$2.01 M
|
$2.85 M
|
-$6.09 M
|
$3.66 M
|
-$160,283.00
|
-$4.06 M
|
-$3.03 M
|
| Gross Profit Ratio |
0.5
|
0.5
|
0.36
|
0.29
|
0.36
|
-1.53
|
0.41
|
-0.05
|
-2.6
|
-2.22
|
| Research and Development Expenses |
$2,370.00
|
$4,836.00
|
$13.14 M
|
$10.01 M
|
$7.89 M
|
$5.35 M
|
$3.04 M
|
$5.04 M
|
$3.25 M
|
$3.05 M
|
| General & Administrative Expenses |
$6,315.00
|
$5,943.00
|
$9.23 M
|
$10.69 M
|
$10.93 M
|
$10.08 M
|
$8.22 M
|
$6.57 M
|
$4.17 M
|
$4.03 M
|
| Selling & Marketing Expenses |
$0.00
|
$701.00
|
$6.10 M
|
$11.34 M
|
$9.57 M
|
$8.99 M
|
$8.94 M
|
$6.84 M
|
$3.30 M
|
$2.19 M
|
| Selling, General & Administrative Expenses |
$6,315.00
|
$6,644.00
|
$15.33 M
|
$22.03 M
|
$20.50 M
|
$19.07 M
|
$17.16 M
|
$13.41 M
|
$7.47 M
|
$6.22 M
|
| Other Expenses |
$378.00
|
$3,916.00
|
$3.35 M
|
$4.60 M
|
$3.06 M
|
$2.70 M
|
$3.51 M
|
$2.62 M
|
$3.22 M
|
$3.73 M
|
| Operating Expenses |
$9,063.00
|
$15,396.00
|
$31.82 M
|
$36.63 M
|
$31.46 M
|
$27.12 M
|
$23.70 M
|
$21.07 M
|
$13.93 M
|
$12.99 M
|
| Cost And Expenses |
$9,193.00
|
$15,896.00
|
$33.98 M
|
$41.52 M
|
$36.57 M
|
$37.20 M
|
$29.00 M
|
$24.63 M
|
$19.56 M
|
$17.39 M
|
| Interest Income |
$12.00
|
$16,000.00
|
$362,000.00
|
$86,000.00
|
$93,000.00
|
$31,000.00
|
$2,000.00
|
$9,108.00
|
$7,454.00
|
$7,512.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$29,000.00
|
$7.03 M
|
$5.01 M
|
$267,031.00
|
| Depreciation & Amortization |
$70.00
|
$164,000.00
|
$397,000.00
|
$435,000.00
|
$457,000.00
|
$432,000.00
|
$335,000.00
|
$279,179.00
|
$315,770.00
|
$324,712.00
|
| EBITDA |
-$8.93 M |
-$14.90 M |
-$33.95 M |
-$35.68 M |
-$28.61 M |
-$33.21 M |
-$19.65 M |
-$21.23 M |
-$17.64 M |
-$15.69 M |
| EBITDA Ratio |
-34.04
|
149.12
|
-9.82
|
-5.03
|
-3.52
|
-8.22
|
-2.2
|
-8.21
|
-11.27
|
-11.47
|
| Operating Income Ratio |
-34.31
|
-14896
|
-10.05
|
-5.1
|
-3.59
|
-8.33
|
-2.24
|
-6.25
|
-11.5
|
-11.72
|
| Total Other Income/Expenses Net |
$8.92 M
|
$14.88 M
|
$362,000.00
|
$586,000.00
|
$93,000.00
|
$31,000.00
|
$29,000.00
|
-$13.97 M
|
-$4.97 M
|
-$257,744.00
|
| Income Before Tax |
-$8,921.00
|
-$14,880.00
|
-$33.59 M
|
-$35.09 M
|
-$28.52 M
|
-$33.18 M
|
-$20.02 M
|
-$35.20 M
|
-$22.97 M
|
-$16.28 M
|
| Income Before Tax Ratio |
-34.31
|
-14.88
|
-9.94
|
-5.09
|
-3.58
|
-8.33
|
-2.24
|
-10.36
|
-14.68
|
-11.91
|
| Income Tax Expense |
$12,000.00
|
$14.88 M
|
$362,000.00
|
$86,000.00
|
$93,000.00
|
$31,000.00
|
$58,000.00
|
-$6.93 M
|
$42,222.00
|
$9,287.00
|
| Net Income |
-$8,921.00
|
-$14,880.00
|
-$33.59 M
|
-$35.09 M
|
-$28.52 M
|
-$33.18 M
|
-$20.02 M
|
-$35.20 M
|
-$22.97 M
|
-$16.28 M
|
| Net Income Ratio |
-34.31
|
-14.88
|
-9.94
|
-5.09
|
-3.58
|
-8.33
|
-2.24
|
-10.36
|
-14.68
|
-11.91
|
| EPS |
-0.0003 |
-0.0005 |
-1.02 |
-1.07 |
-0.87 |
-1.01 |
-0.61 |
-1.07 |
-0.7 |
-0.5 |
| EPS Diluted |
-0.0003 |
-0.0005 |
-1.02 |
-1.07 |
-0.87 |
-1.01 |
-0.61 |
-1.07 |
-0.7 |
-0.5 |
| Weighted Average Shares Out |
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
| Weighted Average Shares Out Diluted |
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
$32.82 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
